Spots Global Cancer Trial Database for Lenalidomide and R-CHOP in B-cell Lymphoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Lenalidomide and R-CHOP in B-cell Lymphoma

Official Title: A Phase IB Study of Escalating Doses of REVLIMID in Association With R-CHOP (R2-CHOP) in the Treatment of B-cell Lymphoma

Study ID: NCT00901615

Conditions

Lymphoma, Large B-Cell, Diffuse

Follicular Lymphoma

Mantle Cell Lymphoma

Marginal Zone Lymphoma

Interventions

Lenalidomide and R-CHOP

Study Description

Brief Summary: The purpose of the study is to determine the recommended dose (RD) of lenalidomide (Revlimid) when administered in association with R-CHOP (rituximab (R), cyclophosphamide, doxorubicin, vincristine and prednisone).

Detailed Description: The study is a dose escalation study of lenalidomide (Revlimid) administered orally during 14 days in combination with fixed doses of rituximab (R), cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks (R-CHOP 21) in patients with B-cell lymphoma.